Ivabradine Hydrochloride API

Name	Ivabradine Hydrochloride
Chinese name	盐酸伊伐布雷定
Cas Number	148849-67-6
Source	India/Europe
Qualifications	USDMF/-/-/-/-

Ivabradine was discovered and developed by the French pharmaceutical company Servier, and was approved in the European Union in October 2005 and February 2012 respectively for the treatment of chronic stable angina pectoris and chronic heart failure. Up to now, Ivabradine has been approved in 122 countries and regions around the world, of which 115 countries have been approved for chronic stable angina and chronic heart failure indications. Ivabradine is a brand-new target therapeutic drug. It selects a specific inhibitor for the first sinus node If current, which can reduce the heart rate of patients with sinus rhythm without affecting myocardial contractility and atrioventricular conduction. It can be used for contraindication or The symptomatic treatment of patients with chronic stable angina pectoris who are intolerant to β-blockers has achieved significant effects in clinical work. This product newly entered China's National Medical Insurance in 2017, and sales will continue to grow rapidly in the next few years, and the market prospects are good. As the patent period approaches, imitation will be a hot spot in the next few years.

Hot Tags: ivabradine hydrochloride api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Oseltamivir Phosphate API, Paliperidone API, Troxagliptin Succinate API, Linagliptin API, Aprepitant Aprepitant API, Bemeprost API

• Previous: Gadoteridol API
• Next: Suvorsen API